{
    "clinical_study": {
        "@rank": "21594", 
        "acronym": "Cyclosporine", 
        "arm_group": [
            {
                "arm_group_label": "Restasis eye drop", 
                "arm_group_type": "Active Comparator", 
                "description": "Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes"
            }, 
            {
                "arm_group_label": "T-sporin eye drop", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic\n      solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12\n      weeks after treatment, each treatment group comparisons for evaluation of efficacy and\n      safety in Moderate to Severe Dry Eye Disease.\n\n      - Corneal staining test, Ocular surface disease index (OSDI), Tear break up time (TBUT),\n      Non-anesthetic Schirmer test"
        }, 
        "brief_title": "Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  [Patients with moderate-to-severe ocular dry eye]\n\n               1. The sum of corneal fluorescein staining score of 5 or higher (NEI Scale)\n\n               2. Non-anesthetic Schirmer test value \u2264 5mm/5min patients at least one eye score\n                  (Non-anesthetic Schirmer test value = 0/5min, nasal stimulation in the same eye,\n                  Schirmer test value \u2265 3mm/5min)\n\n               3. Screening both eyes, the corrected visual acuity is 0.2 or more\n\n               4. Despite conventional treatment, the symptoms of dry eye signs (Artificial tear\n                  eye drops, sympathetic nervous system stimulant agent, parasympathetic nerve\n                  stimulant, etc.)\n\n               5. Negative urine pregnancy test at the screening when women of childbearing age\n\n               6. Medically reliable method of contraception in the case of all women of\n                  childbearing age or menopause (1 year after the last menstrual period women)\n                  Sterilization (eg, bilateral oophorectomy, hysterectomy) women of childbearing\n                  age have not been effective contraception only if you participate in a clinical\n                  trial may have been determined to be pregnant by examining whether the voice,\n                  maintained during the entire clinical trial period shall that.\n\n               7. Written consent voluntarily to participate in this clinical trial\n\n        Exclusion Criteria:\n\n          -  1) Screening visits in the previous 3 months (12 weeks) who participated in the\n             clinical trials of cyclosporine eye drops, or if you used a cyclosporine ophthalmic\n             solutions.\n\n             2) The patients with systemic or ocular disorders affected the test results (ocular\n             surgery, trauma, or disease)\n\n               1. Abnormal eyelid function : Disoders of the eyelids or eyelashes\n\n               2. Ocular allergies or currently under the treatment of allergic diseases of the\n                  eye (topical ocular mast cell stabilizer, antihistamine use, etc.)\n\n               3. Cicatricial keratoconjunctivitis caused by herpetic keratopathy, conjunctival\n                  scarring (alkali damage, Steven-Johnson syndrome, cicatricial pemphigoid),\n                  pterygium, pinguecula, lack of congenital lacrimal, neurogenic keratitis,\n                  keratoconus, corneal transplantation 3) current or recent patients used dry eye\n                  syndrome medications (topical or systemic) that may affect the status 4) The use\n                  in clinical trials of drug hypersensitivity reactions in patients 5) patients\n                  with contact lens 6) If you use or plan to use punctual plug within 4 weeks 7)\n                  Lacrimal punctual occlusion surgery patients 8) Ocular surgery within 3 months\n                  (12 weeks) 9) Pregnant women, lactating, or planning to become pregnant 10) The\n                  end of the lacrimal gland disease (Nasal stimulation Schirmer test value\n                  <3mm/5min) 11) History of malignancy 12) If you are receiving systemic steroids\n                  or immunosuppressive treatment 15) In patients with severe renal failure (serum\n                  creatinine more than 2.0 times the upper limit of normal) 16) In patients with\n                  severe liver dysfunction (ALT or AST of more than 2.0 times the upper limit of\n                  normal) 17) Alcohol or drug abuse 18) Pregnant women, lactating women 19)\n                  Participating in a Clinical Trial patients who have participated in other\n                  clinical trials within three months 20) Patients judged coexisting disease that\n                  could interfere with the completion of the treatment or safety of this clinical\n                  trial. Patients that other researchers are determined inadequately"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768312", 
            "org_study_id": "HL_TSPR_301"
        }, 
        "intervention": {
            "arm_group_label": [
                "Restasis eye drop", 
                "T-sporin eye drop"
            ], 
            "description": "1 drop twice/day for 12 weeks to both eyes", 
            "intervention_name": "Cyclosporine ophthalmic solution", 
            "intervention_type": "Drug", 
            "other_name": [
                "Restasis Eye Drops", 
                "Tisporin Eye Drops"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 11, 2013", 
        "location": {
            "contact": {
                "email": "yeon424@paran.com", 
                "last_name": "Kyu Yeon Hwang, master", 
                "phone": "(822)2258-1188"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Seocho-Ku", 
                    "zip": "137-701"
                }, 
                "name": "The catholic university of Korea seoul st. Mary's hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind Phase \u2162 Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease", 
        "overall_contact": {
            "email": "emkim@hanlim.com", 
            "last_name": "Eun Mi Kim, Bachelor", 
            "phone": "(822)3489-6162"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Corneal staining test", 
            "safety_issue": "No", 
            "time_frame": "Administered 12 weeks after"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768312"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Corneal staining test", 
                "safety_issue": "No", 
                "time_frame": "Administered 4, 8 weeks after"
            }, 
            {
                "measure": "Ocular surface disease index (OSDI)", 
                "safety_issue": "No", 
                "time_frame": "Administered 4, 8, 12 weeks after"
            }, 
            {
                "measure": "Tear break up time (TBUT)", 
                "safety_issue": "No", 
                "time_frame": "Administered 4, 8, 12 weeks after"
            }, 
            {
                "measure": "Non-anesthetic Schirmer test", 
                "safety_issue": "No", 
                "time_frame": "Administered 4, 8, 12 weeks after"
            }, 
            {
                "measure": "Conjunctival staining", 
                "safety_issue": "No", 
                "time_frame": "Administered 4, 8, 12 weeks after"
            }
        ], 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}